Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jun;43(6):507-509.
doi: 10.1007/s40264-020-00935-2.

Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?

Gianluca Trifirò  1 , Salvatore Crisafulli  2 , Giuseppe Andò  3 , Giorgio Racagni  4 , Filippo Drago  5 ; Italian Society of Pharmacology
Collaborators, Affiliations
Editorial

Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?

Gianluca Trifirò et al. Drug Saf. 2020 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

G. Trifirò has served on advisory boards for Sandoz, Hospira, Sanofi, Biogen, Ipsen and Shire; is a consultant for Otsuka; is the principal investigator of observational studies funded by several pharmaceutical companies (e.g. Amgen, AstraZeneca, Daiichi Sankyo, and IBSA) to University of Messina; and is scientific coordinator of the Master’s program ‘Pharmacovigilance, pharmacoepidemiology and pharmacoeconomics: real-world data evaluations’ at University of Messina, which is partly funded by several pharmaceutical companies. G. Andò has received personal fees and non-financial support from Bayer, Pfizer, Bristol Myers Squibb and Boehringer Ingelheim; personal fees from Daiichi Sankyo, Menarini, AstraZeneca, Chiesi and Biosensors; and non-financial support from Terumo, all outside the submitted work. Salvatore Crisafulli, Giorgio Racagni and Filippo Drago have no conflicts of interest that are directly relevant to the content of this commentary.

Comment on

References

    1. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020;2–5. - PMC - PubMed
    1. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. Springer US. 2020 - PMC - PubMed
    1. Watkins J. Preventing a COVID-19 pandemic. BMJ. 2020;368:1–2. - PubMed
    1. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;S2213–2600. - PMC - PubMed
    1. Bavishi C, Bangalore S, Messerli FH. Renin angiotensin aldosterone system inhibitors in hypertension: Is there evidence for benefit independent of blood pressure reduction? Prog Cardiovasc Dis. 2016;59:253–261. doi: 10.1016/j.pcad.2016.10.002. - DOI - PubMed

Substances